| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA690581 | F | Compound concentration which inhibits 80% of serotypes tested, was reported. | Human rhinovirus sp. | 4 | ALA1128705 | organism-based format | Scientific Literature | |
| 2. | ALA693533 | F | Compound was tested for minimum inhibitory concentration against human rhinovirus 14 (HRV14) | Human rhinovirus sp. | 8 | ALA1131109 | organism-based format | Scientific Literature | |
| 3. | ALA879718 | F | Antiviral activity determined by ability to inhibit the HRV-2( human rhinovirus type -2) virus by plaque reduction assay in vitro | human rhinovirus type 2 | 23 | ALA1123677 | organism-based format | Scientific Literature | |
| 4. | ALA696047 | F | Antirhinovirus activity was assessed and the maximum testable concentration that causes no apparent effects on the cell monolayers was determined against HRV-2 virus in vitro. | human rhinovirus type 2 | 26 | ALA1123677 | organism-based format | Scientific Literature | |
| 5. | ALA690986 | F | Negative logarithm of minimal inhibitory concentration against human rhinovirus 14 | 8 | ALA1126676 | assay format | Scientific Literature | ||
| 6. | ALA874124 | F | Minimum inhibitory concentration (antiviral activity) was evaluated n HeLa cells against human rhino virus | Homo sapiens | 12 | ALA1125955 | cell-based format | Scientific Literature | |
| 7. | ALA693207 | F | Maximum testable level (antiviral activity) was evaluated in HeLa cells against human rhino virus | Homo sapiens | 12 | ALA1125955 | cell-based format | Scientific Literature | |
| 8. | ALA695648 | F | Compound concentration required to reduce the viability of mock-infected HeLa cells by 50%, was reported. | Homo sapiens | 4 | ALA1128705 | cell-based format | Scientific Literature | |
| 9. | ALA698789 | F | In vitro concentration required to achieve 50% protection of HeLa cells from HRV-14 induced cytopathic effect | Human rhinovirus sp. | 34 | ALA1128705 | organism-based format | Scientific Literature | |
| 10. | ALA876922 | F | In vitro concentration required to achieve 50% protection of HeLa cells from HRV-2 induced cytopathic effect | 34 | ALA1128705 | cell-based format | Scientific Literature | ||
| 11. | ALA698705 | F | In vitro minimum inhibitory concentration against human rhinovirus-14 (HRV-14) | Human rhinovirus sp. | 13 | ALA1124256 | organism-based format | Scientific Literature | |
| 12. | ALA717607 | F | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 1 mg/kg; Expressed as % nonparalyzed | Mus musculus | 1 | ALA1123069 | organism-based format | Scientific Literature | |
| 13. | ALA717514 | F | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 1 mg/kg; expressed as no. nonparalyzed/total 2/30 | Mus musculus | 1 | ALA1123069 | organism-based format | Scientific Literature | |
| 14. | ALA717515 | F | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 10 mg/kg; Expressed as % nonparalyzed | Mus musculus | 1 | ALA1123069 | organism-based format | Scientific Literature | |
| 15. | ALA717516 | F | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 10 mg/kg; expressed as no. nonparalyzed/total 19/30 | Mus musculus | 1 | ALA1123069 | organism-based format | Scientific Literature | |
| 16. | ALA717517 | F | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 3.3 mg/kg; Expressed as % nonparalyzed | Mus musculus | 1 | ALA1123069 | organism-based format | Scientific Literature | |
| 17. | ALA717518 | F | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 3.3 mg/kg; expressed as no. nonparalyzed/total 6/30 | Mus musculus | 1 | ALA1123069 | organism-based format | Scientific Literature | |
| 18. | ALA717519 | F | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 33 mg/kg; Expressed as % nonparalyzed | Mus musculus | 1 | ALA1123069 | organism-based format | Scientific Literature | |
| 19. | ALA717520 | F | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 33 mg/kg; expressed as no. nonparalyzed/total 29/30 | Mus musculus | 1 | ALA1123069 | organism-based format | Scientific Literature | |
| 20. | ALA717521 | F | Prevention of Echo-9-Induced Paralysis in Suckling mice with Placebo; Expressed as % nonparalyzed | Mus musculus | 1 | ALA1123069 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!